227 related articles for article (PubMed ID: 28642833)
1. Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients.
Srikanthan K; Klug R; Tirona M; Thompson E; Visweshwar H; Puri N; Shapiro J; Sodhi K
J Clin Exp Cardiolog; 2017 Mar; 8(3):. PubMed ID: 28642833
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.
de Vries Schultink AHM; Boekhout AH; Gietema JA; Burylo AM; Dorlo TPC; van Hasselt JGC; Schellens JHM; Huitema ADR
J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):431-442. PubMed ID: 29429038
[TBL] [Abstract][Full Text] [Related]
3. Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients.
Frères P; Bouznad N; Servais L; Josse C; Wenric S; Poncin A; Thiry J; Moonen M; Oury C; Lancellotti P; Bours V; Jerusalem G
BMC Cancer; 2018 Jan; 18(1):102. PubMed ID: 29378531
[TBL] [Abstract][Full Text] [Related]
4. Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
Ponde N; Bradbury I; Lambertini M; Ewer M; Campbell C; Ameels H; Zardavas D; Di Cosimo S; Baselga J; Huober J; Izquierdo M; Fumagalli D; Bozovic-Spasojevic I; Maetens M; Harbeck N; Pusztai L; Berghorn M; Im YH; Borrego MR; Chen DR; Rodeheffer R; Piccart M; Suter T; de Azambuja E
Breast Cancer Res Treat; 2018 Apr; 168(3):631-638. PubMed ID: 29280043
[TBL] [Abstract][Full Text] [Related]
5. [Troponin I and B-type Natriuretic Peptide (BNP) as biomarkers for the prediction of cardiotoxicity in patients with breast cancer treated with adjuvant anthracyclines and trastuzumab].
Pistillucci G; Ciorra AA; Sciacca V; Raponi M; Rossi R; Veltri E
Clin Ter; 2015; 166(1):e67-71. PubMed ID: 25756270
[TBL] [Abstract][Full Text] [Related]
6. Troponin as a cardiotoxicity marker in breast cancer patients receiving anthracycline-based chemotherapy: A narrative review.
Simões R; Silva LM; Cruz ALVM; Fraga VG; de Paula Sabino A; Gomes KB
Biomed Pharmacother; 2018 Nov; 107():989-996. PubMed ID: 30257411
[TBL] [Abstract][Full Text] [Related]
7. Anthracycline or trastuzumab-related cardiotoxicity: do we have a predictive biomarker?
Chaudry M; Banchs J; Chavez-MacGregor M
Biomark Med; 2016; 10(3):315-28. PubMed ID: 26860187
[TBL] [Abstract][Full Text] [Related]
8. High-sensitivity troponin T as a marker to predict cardiotoxicity in breast cancer patients with adjuvant trastuzumab therapy.
Katsurada K; Ichida M; Sakuragi M; Takehara M; Hozumi Y; Kario K
Springerplus; 2014; 3():620. PubMed ID: 25392790
[TBL] [Abstract][Full Text] [Related]
9. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.
Kitayama H; Kondo T; Sugiyama J; Kurimoto K; Nishino Y; Kawada M; Hirayama M; Tsuji Y
Breast Cancer; 2017 Nov; 24(6):774-782. PubMed ID: 28434150
[TBL] [Abstract][Full Text] [Related]
10. Biomarker panel for early screening of trastuzumab -induced cardiotoxicity among breast cancer patients in west virginia.
Pillai SS; Pereira DG; Bonsu G; Chaudhry H; Puri N; Lakhani HV; Tirona MT; Sodhi K; Thompson E
Front Pharmacol; 2022; 13():953178. PubMed ID: 36034829
[TBL] [Abstract][Full Text] [Related]
11. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.
Matos E; Jug B; Blagus R; Zakotnik B
Arq Bras Cardiol; 2016 Jul; 107(1):40-7. PubMed ID: 27305108
[TBL] [Abstract][Full Text] [Related]
12. Alternative Biomarkers for Combined Biology.
Kim YH; Kirsop J; Tang WH
Heart Fail Clin; 2017 Apr; 13(2):381-401. PubMed ID: 28279423
[TBL] [Abstract][Full Text] [Related]
13. Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients.
De Iuliis F; Salerno G; Taglieri L; De Biase L; Lanza R; Cardelli P; Scarpa S
Tumour Biol; 2016 Mar; 37(3):3379-87. PubMed ID: 26449821
[TBL] [Abstract][Full Text] [Related]
14. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
[TBL] [Abstract][Full Text] [Related]
15. Left Ventricular Systolic Dysfunction Predicted By Early Troponin I Release After Anthracycline Based Chemotherapy In Breast Cancer Patients.
Shafi A; Siddiqui N; Imtiaz S; Din Sajid MU
J Ayub Med Coll Abbottabad; 2017; 29(2):266-269. PubMed ID: 28718245
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults.
Dodos F; Halbsguth T; Erdmann E; Hoppe UC
Clin Res Cardiol; 2008 May; 97(5):318-26. PubMed ID: 18193371
[TBL] [Abstract][Full Text] [Related]
17. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
[TBL] [Abstract][Full Text] [Related]
18. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
[TBL] [Abstract][Full Text] [Related]
19. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers as Predictors of Cardiac Toxicity From Targeted Cancer Therapies.
Witteles RM
J Card Fail; 2016 Jun; 22(6):459-64. PubMed ID: 27038641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
